Latest market price
25.87
+0.74+2.94%
OverviewShort InterestFilings
RAPPQT14Rapport Therapeutics, Inc. Common Stock·NASDAQ
25.87+2.94%
Earnings
Up 2.9% — Earnings due 2026-11-05 — pre-report positioning.
Medium confidence
TA
Loading chart...
Signal & projected range
Insider open-market buyHistorical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
QURE+0.30%$23.04RARE+2.39%$16.69NUVB+2.35%$4.70TRAX+1.17%$45.58NTLA+3.95%$12.12ABSI+5.42%$10.21URGN-0.50%$34.19MAZE+1.94%$30.96
Snapshot
Index—P/E—EPS (ttm)-3.04Insider Own33.40%Shs Outstand47.98MPerf Week-0.79%
Market Cap1.21BForward P/E—EPS next Y-4.94Insider Trans2.66%Shs Float22.95MPerf Month-21.88%
Enterprise Value777.69MPEG—EPS next Q-1.20Short Float13.30%Perf Quarter-40.45%
Income-138.00MP/S60.28EPS this Y—Short Ratio8.74Perf Half Y-29.27%
Sales20.00MP/B2.85EPS next Y—ROA-29.88%Short Interest3.05MPerf YTD-17.17%
Book/sh8.82P/C2.77EPS next 5Y—ROE-29.02%52W High52.93 -51.12%Perf Year-6.51%
Cash/sh9.09P/FCF—EPS past 3/5Y—ROIC-35.45%52W Low22.06 17.27%Perf 3Y—
Dividend Est.—EV/EBITDA—Sales past 3/5Y—Gross Margin—Volatility9.63% 8.13%Perf 5Y—
Dividend TTM—EV/Sales38.88EPS Y/Y TTM—Oper. Margin-767.58%ATR (14)2.63Perf 10Y—
Dividend Ex-Date—Quick Ratio15.72Sales Y/Y TTM—Profit Margin-685.80%RSI (14)37.81Recom2.00
Dividend Gr. 3/5Y—Current Ratio15.72EPS Q/Q-58.67%SMA20-9.01%Beta1.07Target Price65.56
Payout0.00%Debt/Eq0.02Sales Q/Q—SMA50-30.66%Rel Volume1.85Prev Close25.13
Employees84LT Debt/Eq0.02EarningsNov 05SMA200-29.49%Avg Volume718.13KPrice25.87
IPO DateJun 07, 2024Option/ShortYes / YesEPS/Sales Surpr.-23.56% —Net Debt/EBITDA—Volume1,327,415Change2.94%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-21-26ReiteratedWells FargoOverweight$43 → $50
Oct-20-26ReiteratedRaymond James$75 → $86
Oct-20-26ReiteratedBTIGBuy$75 → $89
Oct-15-26InitiatedWolfe ResearchOutperform$50
Oct-15-26InitiatedUBSBuy$80 → $71
Oct-05-26InitiatedGuggenheimBuy$65
Sep-23-26ReiteratedUBS$80
Sep-16-26ReiteratedBTIGBuy$65 → $75
Aug-17-26ReiteratedRaymond James$66 → $75
Aug-12-26ReiteratedHC Wainwright & Co.Buy$40 → $66
Latest News· Times ET
Today
Today07:00AM
Rapport Therapeutics to Participate in Upcoming Investor Conferencesglobenewswire.com
Oct-28-26
Oct-28-2610:59AM
Rapport Therapeutics Prices Stock, Convertible Notes Offerings; Private Placement; Shares FallYahoo
06:00AM
Rapport Announces Pricing of Underwritten Offerings of Common Stock and Pre-Funded Warrants and Convertible Notes and Concurrent Private Placementglobenewswire.com
Oct-27-26
Oct-27-2604:32PM
Rapport Announces Proposed Public Offerings of Common Stock and Convertible Notes as well as Concurrent Private Placementglobenewswire.com
Oct-26-26
Oct-26-2604:52AM
Insider Selling: Rapport Therapeutics (NASDAQ:RAPP) CEO Sells $64,443.60 in Stockdefenseworld.net
Oct-25-26
Oct-25-2601:02PM
Rapport Therapeutics' RAP-219 Hits Phase II Goals in Bipolar Mania Trialmarketbeat.com
Oct-21-26
Oct-21-2608:28AM
Jones Trading Maintains Buy on Rapport Therapeutics, Raises Price Target to $82Benzinga
Oct-20-26
Oct-20-2604:54PM
Rapport Therapeutics, Inc. (RAPP) Discusses Phase II Bipolar Mania Trial Results and Business Update Transcriptseekingalpha.com
09:31AM
Why Is Rapport Therapeutics Stock Trading Higher Today?benzinga.com
09:14AM
Inside the $1 Billion Blockbuster Opportunity That Has Rapport Therapeutics Stock Surgingbarrons.com
06:00AM
Rapport Therapeutics Announces Positive Topline Results from its Phase 2 Trial of RAP-219 for the Treatment of Bipolar Maniaglobenewswire.com
Oct-15-26
Oct-15-2604:00AM
Wolfe Research Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $50Benzinga
Oct-06-26
Oct-06-2604:02AM
Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65Benzinga
Sep-24-26
Sep-24-2611:56AM
Rapport: Bipolar Mania Readout May Distort True Value Of Anti-Seizure Med - Rating Upgradeseekingalpha.com
Sep-23-26
Sep-23-2601:32PM
Rapport Therapeutics, Inc. (RAPP) Discusses RAP-219 Phase II Trial and Unmet Needs in Bipolar Mania - SlideshowSeekingAlpha
Company

Rapport Therapeutics, Inc. functions as a clinical-phase biopharmaceutical enterprise, concentrating its efforts on discovering and developing innovative small-molecule therapeutics for individuals living with central nervous system (CNS) disorders. Its flagship product candidate, RAP-219, is an experimental small molecule precisely designed to inhibit TARPy8-containing AMPARs with exceptional potency (picomolar affinity). This promising compound aims to treat focal epilepsy and a range of other neurological conditions, including peripheral neuropathic pain and bipolar disorder. The company's pipeline further includes RAP-199, another molecule targeting TARPy8, which boasts distinct chemical and pharmacokinetic profiles. Moreover, Rapport is advancing several nicotinic acetylcholine receptor (nAChR) programs, such as an a6 nAChR therapy for chronic pain and an a9a10 nAChR treatment intended for hearing impairments. Formed in 2022 under the initial name Precision Neuroscience NewCo, Inc., the company adopted its current identity as Rapport Therapeutics, Inc. in October 2022, and its operations are based in Boston, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
Total Revenue
20000—
Cost of Goods Sold Incl. D&A
0000—
Gross Profit
20000—
Selling, General and Administrative Excl. Other3630228—
Research and Development136956128—
Other Operating Expense
2000—
Operating Income-154-125-83-36—
Interest Expense
0000—
Unusual Expense
—————
Non-Operating Income (Expense)161451—
Net Income Before Taxes-138-111-78-35—
Income Taxes
0000—
Consolidated Net Income-138-111-78-35—
Net Income From Continuing Operations-138-111-78-35—
Net Income-138-111-78-35—
EPS (Recurring)-3.04-2.86-3.78-0.95—
EPS (Basic, Before Extraordinaries)-3.04-2.86-3.78-0.95—
EPS (Diluted)-3.04-2.86-3.78-0.95—
EBITDA-148-124-82-36—
Other After Tax Adjustments
—————
Stock Option Compensation Expense
—————
Price To Earnings Ratio
—————
Price To Sales Ratio
60.79————
Gross Margin
100.00————
Operating Margin
-770.00————
Net Margin
-690.00————
Shares Outstanding47472118—
Market Capitalization1,2161,426373——
Operating Lease Expense
—————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$58.22$45.83$33.43$21.03$8.64● Close Price0.00M5.51M11.01M16.52M22.02MUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
HEALY JAMESDirectorOct 28 '26Buy21.00969,48020,359,0802,815,707Oct 30
Sanchez RamiroDirectorOct 23 '26Buy27.353,60098,4783,600Oct 23
Ceesay AbrahamChief Executive OfficerOct 21 '26Sale29.162,21064,448450,035Oct 23
MARAGANORE JOHNDirectorOct 22 '26Buy26.459,411248,8919,411Oct 22
Silva Paul MDirectorOct 22 '26Buy27.073,68099,6363,680Oct 22
Young Wendy B.DirectorOct 22 '26Buy26.393,78999,99213,289Oct 22
PAUL STEVEN MDirectorOct 22 '26Buy27.2835,714974,27877,380Oct 22
Ignelzi Troy A.Chief Financial OfficerOct 21 '26Buy26.105,500143,55015,500Oct 21
Ceesay AbrahamChief Executive OfficerOct 07 '26Sale30.661,14735,167452,245Oct 08
Ceesay AbrahamChief Executive OfficerOct 06 '26Sale32.033,375108,106453,392Oct 08
Gault CherylChief Operating OfficerSep 30 '26Sale33.1910,000331,856139,914Oct 01
Ceesay AbrahamChief Executive OfficerSep 23 '26Sale39.172,21086,565456,767Sep 24
Ceesay AbrahamChief Executive OfficerSep 08 '26Sale45.618,210374,498458,977Sep 09
Ceesay AbrahamChief Executive OfficerAug 25 '26Sale49.5718,921937,957467,187Aug 26
Yeleswaram KrishnaswamyChief Development OfficerAug 25 '26Sale50.6437,0001,873,605195,862Aug 26
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.